New hope for Hard-to-Treat colon cancer? study tests targeted drug combo
Disease control
Terminated
This study tested whether adding the experimental drug ompenaclid to standard chemotherapy could shrink tumors in people with advanced colorectal cancer that has a RAS gene mutation. About 76 participants were randomly assigned to receive either ompenaclid or a placebo, along wit…
Phase: PHASE2 • Sponsor: Inspirna, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC